A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Completed
Bayer
Phase 3
2008-06-01
ALSYMPCA (ALpharadin in SYMPtomatic Prostate CAncer) is an international Phase III clinical
study to evaluate the efficacy and safety of Radium-223 dichloride in patients with hormone
refractory prostate cancer and skeletal metastases.
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
No longer available
Bayer
1969-12-31
This study is a prospective, interventional, open-label, multi-center early access program
for the use of Ra-223 Cl2 in HRPC/CRPC patients diagnosed with symptomatic bone metastasis
and to collect additional short and long term safety data on the product.
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Completed
Bayer
Phase 3
2012-07-22
This study is a prospective, interventional, open-label, multi-center early access program
for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate
resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional
short and long term safety data on the product.
Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
Completed
Bayer
Phase 3
2013-03-26
To evaluate the safety and efficacy (Overall survival [OS]) of multiple doses of Ra-223
dichloride in an Asian population of subjects with CRPC metastatic to the bone.
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
Completed
Bayer
Phase 1/Phase 2
2013-10-16
The goal of this clinical research study is to find the highest tolerable dose of radium-223
dichloride that can be given to patients with osteosarcoma.
Radium-223 chloride is designed to work like radiation therapy in cells that are actively
making bone. It is designed to target new bone growth in and around bone cancer and may kill
cancer cells.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
